Key Drivers
- High gross margin
- Improving FCF
- Persistent losses
AIAI Summary
Teladoc should be valued primarily as an Integrated Care growth and margin-recovery story with BetterHelp as contingent upside—investors should therefore demand clear, sustained Integrated Care visit/revenue growth and BetterHelp insurance-driven membership/ARPU stabilization plus demonstrable OPEX cuts and debt reduction before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Improving FCF
- •Persistent losses
Teladoc combines strong revenue and very high gross margins with improving free cash flow and a solid cash balance, but persistent annual net losses, high operating expenses and moderate debt keep accounting profitability and returns negative.
Price Behavior
Key Price Behavior Insights:
- •Above moving average
- •18% recovery
- •Resistance congestion
TDOC is in a modest short-term uptrend—price above the last-month average (~$5.19) and an ~18% rally from the late‑Feb $4.54 low to $5.35 close, with near-term resistance around $5.60–$5.62 and support at $5.00–$5.10 (break below $5.00/$4.54 would weaken the recovery).
~18% gain from $4.54 (late‑Feb) to $5.35 close indicating sharp short-term recovery
Sentiment & News
Key News Insights:
- •International growth
- •Integrated Care strength
- •BetterHelp weakness
Teladoc topped Q4 revenue and narrowed its loss driven by international growth and cost cuts, but mixed segment trends (Integrated Care up, BetterHelp down), analyst cuts and post-earnings volatility leave the outlook uncertain.
The results and commentary suggest near-term upside from cost discipline and international momentum, but uneven segment performance and analyst downgrades increase execution risk for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings